GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Amantadine (source heading: Amantidine)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Before use: Amantadine (source heading: Amantidine)

The retrieved SYMMETREL mirror uses 100 mg every 7 days below 15, while the US IR capsule label uses 200 mg every 7 days. Other interval bands and first-dose instructions also differ; mirror jurisdiction/applicability is unreconciled.

Before applying: Treat the SYMMETREL mirror as a source-quality hold. Do not apply its schedule to the US IR capsule or an extended-release product.

Evidence for this qualification

Source-specific interpretation; independent clinician adjudication pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Amantadine immediate-release capsules - Alembic US label

Product / population
Immediate-release 100 mg capsules; adult renal instructions. Not GOCOVRI or OSMOLEX ER.
Renal measure
Source prints indexed creatinine clearance, mL/min/1.73 m2.
Before using this finding

For the US immediate-release product use its applicable official label; do not blend the conflicting mirror interval or extend the table to ER products.

Renal guidance and important limits

Limits that apply to these rows

Renal accumulation has caused fatal toxicity when doses exceeded recommendations. Hemodialysis removes negligible amounts.

Monitor CNS effects, edema and orthostatic hypotension. Do not abruptly discontinue in Parkinson disease. Historical influenza indications are not a current antiviral recommendation.

Amantadine immediate-release - US label renal table
Indexed CrCl (mL/min/1.73 m2)Source-specific instruction
30-50200 mg on day 1, then 100 mg daily
15-29200 mg on day 1, then 100 mg on alternate days
<15200 mg every 7 days
Dialysis guidance - separate source-specific schedules
Amantadine immediate-release - US label HD
SettingSource-specific instruction
Hemodialysis200 mg every 7 days
Read the retained text before reformatting

Amantadine immediate-release - US label renal table

Indexed CrCl (mL/min/1.73 m2)Source-specific instruction
30-50200 mg on day 1, then 100 mg daily
15-29200 mg on day 1, then 100 mg on alternate days
<15200 mg every 7 days

Amantadine immediate-release - US label HD

SettingSource-specific instruction
Hemodialysis200 mg every 7 days

Renal accumulation has caused fatal toxicity when doses exceeded recommendations. Hemodialysis removes negligible amounts.

Monitor CNS effects, edema and orthostatic hypotension. Do not abruptly discontinue in Parkinson disease. Historical influenza indications are not a current antiviral recommendation.

Source revision: 06/2025 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4157d9a7-a53f-4dde-b051-fe3e9a674913

Scope: Selected source sections stored locally. Not a complete monograph or independent clinical approval. GlobalRPh v6.6.

Full source card / provenance

Other formulations / related references (2)

Confirm the exact product. These links do not imply interchangeable doses or indications.

GOCOVRI extended-release capsules: February 2026 labelRelated reference only; not an interchangeable dose or indication.Amantadine - OSMOLEX ER tabletsRelated reference only; not an interchangeable dose or indication.
All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Official product label

Amantadine immediate-release capsules - Alembic US label

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

For the US immediate-release product use its applicable official label; do not blend the conflicting mirror interval or extend the table to ER products.

Immediate-release 100 mg capsules; adult renal instructions. Not GOCOVRI or OSMOLEX ER.

Renal method: Source prints indexed creatinine clearance, mL/min/1.73 m2.
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - SYMMETREL

Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Before using this finding

Treat the SYMMETREL mirror as a source-quality hold. Do not apply its schedule to the US IR capsule or an extended-release product.

Historical SYMMETREL mirror; jurisdiction and exact marketed-product applicability unresolved.

Renal method: Printed indexed CrCl, mL/min/1.73 m2.
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Before use: Amantadine (source heading: Amantidine)

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source scope and renal guidance

Before use: Amantadine (source heading: Amantidine)

The retrieved SYMMETREL mirror uses 100 mg every 7 days below 15, while the US IR capsule label uses 200 mg every 7 days. Other interval bands and first-dose instructions also differ; mirror jurisdiction/applicability is unreconciled.

How to use this: Treat the SYMMETREL mirror as a source-quality hold. Do not apply its schedule to the US IR capsule or an extended-release product.

Amantadine immediate-release capsules - Alembic US labelGlobalRPh RX List - SYMMETREL

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeAmantadine immediate-release capsules - Alembic US labelGlobalRPh RX List - SYMMETREL
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The live source uses the spelling Amantidine in its heading and URL; amantadine is retained as the searchable ingredient name. This is not a modified-release amantadine protocol.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/amantidine/

Usual Dosing (Adults) - historical influenza content

Dosage for Prophylaxis and Treatment of Uncomplicated Influenza A Virus Illness

Adult: The adult daily dosage of Amantadine Hydrochloride Capsules, USP is 200 mg; two 100 mg capsules as a single daily dose. The daily dosage may be split into one capsule of 100 mg twice a day. If central nervous system effects develop in once-a-day dosage, a split dosage schedule may reduce such complaints. In persons 65 years of age or older, the daily dosage of Amantadine Hydrochloride Capsules, USP is 100 mg.

A 100 mg daily dose has also been shown in experimental challenge studies to be effective as prophylaxis in healthy adults who are not at high risk for influenza-related complications. However, it has not been demonstrated that a 100 mg daily dose is as effective as a 200 mg daily dose for prophylaxis, nor has the 100 mg daily dose been studied in the treatment of acute influenza illness.

In recent clinical trials, the incidence of central nervous system (CNS) side effects associated with the 100 mg daily dose was at or near the level of placebo. The 100 mg dose is recommended for persons who have demonstrated intolerance to 200 mg of Amantadine Hydrochloride Capsules, USP daily because of CNS or other toxicities. Prophylactic dosing should be started in anticipation of an influenza A outbreak and before or after contact with individuals with influenza A virus respiratory tract illness.

Amantadine Hydrochloride Capsules, USP should be continued daily for at least 10 days following a known exposure. If Amantadine Hydrochloride Capsules, USP are used chemoprophylactically in conjunction with inactivated influenza A virus vaccine until protective antibody responses develop, then it should be administered for 2 to 4 weeks after the vaccine has been given.

When inactivated influenza A virus vaccine is unavailable or contraindicated, Amantadine Hydrochloride Capsules, USP should be administered for the duration of known influenza A in the community because of repeated and unknown exposure. Treatment of influenza A virus illness should be started as soon as possible, preferably within 24 to 48 hours after onset of signs and symptoms, and should be continued for 24 to 48 hours after the disappearance of signs and symptoms.

GRPH-amantidine-01 · Source section: Usual Dosing (Adults) - historical influenza contentRenal section finder

Dosage for Parkinsonism

Adult: The usual dose of Amantadine Hydrochloride Capsules, USP is 100 mg twice a day when used alone. Amantadine Hydrochloride Capsules, USP have an onset of action usually within 48 hours. The initial dose of Amantadine Hydrochloride Capsules, USP is 100 mg daily for patients with serious associated medical illnesses or who are receiving high doses of other antiparkinson drugs. After one to several weeks at 100 mg once daily, the dose may be increased to 100 mg twice daily, if necessary.

Occasionally, patients whose responses are not optimal with Amantadine Hydrochloride Capsules, USP at 200 mg daily may benefit from an increase up to 400 mg daily in divided doses. However, such patients should be supervised closely by their physicians. Patients initially deriving benefit from Amantadine Hydrochloride Capsules, USP not uncommonly experience a fall-off of effectiveness after a few months. Benefit may be regained by increasing the dose to 300 mg daily.

Alternatively, temporary discontinuation of Amantadine Hydrochloride Capsules, USP for several weeks, followed by reinitiation of the drug, may result in regaining benefit in some patients. A decision to use other antiparkinson drugs may be necessary.

GRPH-amantidine-02 · Source section: Dosage for ParkinsonismRenal section finder

Dosage for Concomitant Therapy

Some patients who do not respond to anticholinergic antiparkinson drugs may respond to Amantadine Hydrochloride Capsules, USP. When Amantadine Hydrochloride Capsules, USP or anticholinergic antiparkinson drugs are each used with marginal benefit, concomitant use may produce additional benefit. When Amantadine Hydrochloride Capsules, USP and levodopa are initiated concurrently, the patient can exhibit rapid therapeutic benefits.

Amantadine Hydrochloride Capsules, USP should be held constant at 100 mg daily or twice daily while the daily dose of levodopa is gradually increased to optimal benefit. When Amantadine Hydrochloride Capsules, USP is added to optimal well-tolerated doses of levodopa, additional benefit may result, including smoothing out the fluctuations in improvement which sometimes occur in patients on levodopa alone.

Patients who require a reduction in their usual dose of levodopa because of development of side effects may possibly regain lost benefit with the addition of Amantadine Hydrochloride Capsules, USP.

GRPH-amantidine-03 · Source section: Dosage for Concomitant TherapyRenal section finder

Dosage for Drug-Induced Extrapyramidal Reactions

Adult: The usual dose of Amantadine Hydrochloride Capsules, USP is 100 mg twice a day. Occasionally, patients whose responses are not optimal with Amantadine Hydrochloride Capsules, USP at 200 mg daily may benefit from an increase up to 300 mg daily in divided doses.

GRPH-amantidine-04 · Source section: Dosage for Drug-Induced Extrapyramidal ReactionsRenal section finder

Renal Dosing

Oral:

[>50 ml/min]: No change

[30-50]: 200mg x 1, then 100 mg q24h

[15-29]: 200mg x 1, then 100mg q48h

[<15 ml/min]: 200mg q 7 days

GRPH-amantidine-05 · Source section: Renal DosingRenal section finder

Hemodialysis

Administer 200 mg every 7 days

GRPH-amantidine-06 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Amantadine immediate-release capsules - Alembic US label

Open original reference

Open / share this exact local source

DailyMed / NLM exact product labeling · Immediate-release 100 mg capsules; adult renal instructions. Not GOCOVRI or OSMOLEX ER.

Renal method: Source prints indexed creatinine clearance, mL/min/1.73 m2.
Source date: 06/2025
Retrieved: 2026-09-10

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

For the US immediate-release product use its applicable official label; do not blend the conflicting mirror interval or extend the table to ER products.

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

Renal accumulation has caused fatal toxicity when doses exceeded recommendations. Hemodialysis removes negligible amounts.

Monitor CNS effects, edema and orthostatic hypotension. Do not abruptly discontinue in Parkinson disease. Historical influenza indications are not a current antiviral recommendation.

Amantadine immediate-release - US label renal table
Indexed CrCl (mL/min/1.73 m2)Source-specific instruction
30-50200 mg on day 1, then 100 mg daily
15-29200 mg on day 1, then 100 mg on alternate days
<15200 mg every 7 days
Dialysis guidance - separate source-specific schedules
Amantadine immediate-release - US label HD
SettingSource-specific instruction
Hemodialysis200 mg every 7 days
Read the retained text before reformatting

Amantadine immediate-release - US label renal table

Indexed CrCl (mL/min/1.73 m2)Source-specific instruction
30-50200 mg on day 1, then 100 mg daily
15-29200 mg on day 1, then 100 mg on alternate days
<15200 mg every 7 days

Amantadine immediate-release - US label HD

SettingSource-specific instruction
Hemodialysis200 mg every 7 days

Renal accumulation has caused fatal toxicity when doses exceeded recommendations. Hemodialysis removes negligible amounts.

Monitor CNS effects, edema and orthostatic hypotension. Do not abruptly discontinue in Parkinson disease. Historical influenza indications are not a current antiviral recommendation.

RDM64-official-amantidine-b8a48f2047-C1 · Source locator: Dosage for Impaired Renal Function; warnings; renal PK.

Source-specific limits

Renal accumulation has caused fatal toxicity when doses exceeded recommendations. Hemodialysis removes negligible amounts.

Monitor CNS effects, edema and orthostatic hypotension. Do not abruptly discontinue in Parkinson disease. Historical influenza indications are not a current antiviral recommendation.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4157d9a7-a53f-4dde-b051-fe3e9a674913
Retrieved
2026-09-10
Exact label title
Amantadine immediate-release capsules - Alembic US label
DailyMed Set ID
4157d9a7-a53f-4dde-b051-fe3e9a674913
Label revision
06/2025
Renal-function method
Source prints indexed creatinine clearance, mL/min/1.73 m2.
Source date/version
06/2025
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
07971343023528483b299fb2ce011d7f51f71e63c97c00d19da4620157ef56eb
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - SYMMETREL

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Historical SYMMETREL mirror; jurisdiction and exact marketed-product applicability unresolved.

Renal method: Printed indexed CrCl, mL/min/1.73 m2.
Source date: April 2019 (printed Novartis mirror revision)
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Before using this finding

Treat the SYMMETREL mirror as a source-quality hold. Do not apply its schedule to the US IR capsule or an extended-release product.

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

The mirror headings overlap at 25 and 35. This card records a conflict rather than endorsing a second renal algorithm.

Use exact-product official labeling; low hemodialysis removal does not resolve the dose disagreement.

Mirror conflict - NOT the US label schedule
Source observationSource-specific instruction
CrCl <15The mirror says 100 mg every 7 days, versus 200 mg every 7 days in the US IR label.
Other bands / first doseThe mirror uses different interval bands and indication-specific first doses. Do not combine them with the US schedule.
Read the retained text before reformatting

Mirror conflict - NOT the US label schedule

Source observationSource-specific instruction
CrCl <15The mirror says 100 mg every 7 days, versus 200 mg every 7 days in the US IR label.
Other bands / first doseThe mirror uses different interval bands and indication-specific first doses. Do not combine them with the US schedule.

The mirror headings overlap at 25 and 35. This card records a conflict rather than endorsing a second renal algorithm.

Use exact-product official labeling; low hemodialysis removal does not resolve the dose disagreement.

RDM64-rxlist-amantidine-06b1d14b7a-C1 · Source locator: Renal Impairment Table 1, preceding first-dose paragraph and Hemodialysis.

Source-specific limits

The mirror headings overlap at 25 and 35. This card records a conflict rather than endorsing a second renal algorithm.

Use exact-product official labeling; low hemodialysis removal does not resolve the dose disagreement.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/symmetrel-drug/
Retrieved
2026-09-10
Renal-function method
Printed indexed CrCl, mL/min/1.73 m2.
Source date/version
April 2019 (printed Novartis mirror revision)
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
900f51e459f6cced24c588eb82ad79ecde4e273cfa267fbb800f014b214a505b

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/amantidine/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
524af1dd0c7ddc7024f03e592e21e0cd168a7767c6f451f8dee7ea447b687451
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report